Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ULK1 | O75385 | 2/20 | 0.70 |
| ▸ | EGFR | P00533 | 8/20 | 0.66 |
| ▸ | BTK | Q06187 | 2/20 | 0.66 |
| ▸ | PTK2 | Q05397 | 6/20 | 0.59 |
| ▸ | MET | P08581 | 3/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.59 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.59 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.59 |
| ▸ | CDC7 | O00311 | 1/20 | 0.59 |
| ▸ | PLK4 | O00444 | 1/20 | 0.59 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.59 |
| ▸ | AURKA | O14965 | 1/20 | 0.59 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.59 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.59 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.59 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.59 |
| ▸ | JAK2 | O60674 | 1/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | PAK4 | O96013 | 1/20 | 0.59 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25001794 | 0.88 | EGFR (0.84) | ULK1EGFRBTKALKINSR | |
| SCHEMBL25001951 | 0.87 | EGFR (0.66) | ULK1EGFRBTKALKMAPK9 | |
| SCHEMBL25001489 | 0.86 | EGFR (0.84) | ULK1EGFRBTKALKLRRK2 | |
| SCHEMBL25821864 | 0.85 | EGFR (0.64) | ULK1EGFRBTKALKJAK2 | |
| SCHEMBL25824760 | 0.85 | EGFR (0.62) | ULK1EGFRBTKALKJAK2 | |
| SCHEMBL30748473 | 0.85 | EGFR (0.68) | ULK1EGFRBTKALKINSR | |
| SCHEMBL25001760 | 0.85 | EGFR (0.68) | ULK1EGFRBTKALKINSR | |
| SCHEMBL25001487 | 0.85 | EGFR (0.76) | ULK1EGFRBTKALKROS1 | |
| SCHEMBL25002762 | 0.85 | EGFR (0.65) | ULK1EGFRBTKALKLRRK2 | |
| SCHEMBL30140980 | 0.84 | EGFR (0.66) | ULK1EGFRBTKALKLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112538072-B | Aminopyrimidine EGFR inhibitors | 齐鲁制药有限公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| EP-4129996-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-08 | — | — | EP | disclosed |
| CN-112538072-A | Novel aminopyrimidine EGFR (epidermal growth factor receptor) inhibitor | 齐鲁制药有限公司 | 2021-03-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219986-A1 | NOVEL AMINOPYRIMIDINE EGFR INHIBITOR | EGFR, ERBB2, ERBB4 | ULK1 1059/4885EGFR 1/4885BTK 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.